Efficacy of Bevacizumab in Preventing Acute Respiratory Distress Syndrome (ARDS)
Status:
Withdrawn
Trial end date:
2016-02-01
Target enrollment:
Participant gender:
Summary
This study aims to test the effectiveness of a single intravenous (IV, through the vein) dose
of the study drug, bevacizumab (Avastin), in preventing/reducing the development of Acute
Respiratory Distress Syndrome (ARDS), in patients with severe sepsis, who are at high risk
for developing ARDS. ARDS is a lung disease caused by a lung injury that leads to lung
function impairment. The condition the patient has,severe sepsis, is a medical condition
associated with an infection characterized as an immune system inflammatory response
throughout your whole body that can lead to organ dysfunction, low blood pressure or
insufficient blood flow to one or more of your organs.